FDA Aligns Quality Regs with ISO Standard

The FDA's new Quality Management System Regulation (QMSR) officially took effect on February 2, 2026, replacing the Quality System Regulation (QSR) that had been in place for decades. This new rule incorporates the international standard ISO 13485:2016 by reference, meaning its requirements are now part of U.S. law for medical device manufacturers. The transition aims to harmonize U.S. regulations with the global standard, a move intended to reduce the burden on manufacturers who previously had to comply with two different systems. This isn't a simple name change; the QMSR fundamentally alters how the FDA inspects and enforces quality systems. The agency has retired its long-standing Quality System Inspection Technique (QSIT) and implemented a new risk-based inspection process aligned with the QMSR. This new approach focuses more on a company's overall quality management processes rather than a checklist-style audit. A critical change for manufacturers is the expanded scope of FDA inspections. Previously, records from internal audits, management reviews, and supplier audits were largely exempt from FDA review. Under the new QMSR, these documents are now subject to inspection, demanding a higher level of rigor and transparency in internal processes. The alignment brings a new vocabulary to U.S. regulations, adopting terms from ISO 13485. For instance, the "Device Master Record" is now referred to as the "Medical Device File." While the FDA has aligned with the international standard, it has retained some U.S.-specific requirements, particularly around labeling, packaging controls, and traceability records to ensure consistency with existing American laws. Companies that were already compliant with ISO 13485 will have a smoother transition, but a gap analysis is still necessary to ensure all FDA-specific provisions are met.